HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT01487083

A Long-Term Safety Study of Pomaglumetad Methionil in Schizophrenia

Researchers are studying Pomaglumetad methionil, tracking side effects to assess long-term safety in people with schizophrenia.

Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

What is this study about?

Researchers are studying Pomaglumetad methionil, tracking side effects to assess long-term safety in people with schizophrenia.

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
Cerritos and 50 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateDecember 2011
Recruitment status
Terminated
Enrollment listed in the registry
129
Sponsor
Denovo Biopharma LLC
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, France, Austria, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01487083
Official title
Show the full official title

Long-Term Open-Label Safety Study of Pomaglumetad Methionil in Patients With Schizophrenia

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Terminated

Cerritos, United States · Escondido, United States · Garden Grove, United States

48 more locations
  • Long Beach, United States
  • San Diego, United States
  • Sherman Oaks, United States
  • Torrance, United States
  • Washington D.C., United States
  • Coral Gables, United States
  • Lauderhill, United States
  • Maitland, United States
  • North Miami, United States
  • Oakland Park, United States
  • Sanford, United States
  • Chicago, United States
  • Indianapolis, United States
  • Lake Charles, United States
  • Flowood, United States
  • Creve Coeur, United States
  • Marlton, United States
  • Princeton, United States
  • Brooklyn, United States
  • Cedarhurst, United States
  • Fresh Meadows, United States
  • Rochester, United States
  • Staten Island, United States
  • Charlotte, United States
  • Beachwood, United States
  • Oklahoma City, United States
  • Eugene, United States
  • Allentown, United States
  • Philadelphia, United States
  • Austin, United States
  • DeSoto, United States
  • Wharton, United States
  • Richmond, United States
  • Vienna, Austria
  • Salvador, Brazil
  • São Paulo, Brazil
  • Limoges, France
  • Dresden, Germany
  • Oranienburg, Germany
  • Chaïdári, Greece
  • Bialystok, Poland
  • Gdynia, Poland
  • San Juan, Puerto Rico
  • Bucharest, Romania
  • Madrid, Spain
  • Vic, Spain
  • Luleå, Sweden
  • Malmö, Sweden
Checked Official study record (opens in a new tab)

A listed location does not confirm current availability.

FAQ

Questions about this study

What is this study about?

Researchers are studying Pomaglumetad methionil, tracking side effects to assess long-term safety in people with schizophrenia.

Who is behind this study?

The study sponsor is Denovo Biopharma LLC.

Does this study involve medication?

Yes. The study involves medication, including Pomaglumetad methionil.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies